Y. Tsujimoto and C. M. Croce, Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma, Proc Natl Acad Sci, vol.83, pp.5214-5222, 1986.

J. M. Adams and C. S. , The Bcl-2 protein family: arbiters of cell survival, Science, vol.281, pp.1322-1328, 1998.

A. Frenzel, F. Grespi, W. Chmelewskij, and A. Villunger, Bcl2 family proteins in carcinogenesis and the treatment of cancer, Apoptosis, vol.14, pp.584-96, 2009.

J. C. Reed, Bcl-2 and the regulation of programmed cell death, J Cell Biol, vol.124, pp.1-6, 1994.

G. M. Callagy, M. J. Webber, P. D. Pharoah, and C. Caldas, Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer, BMC Cancer, vol.8, p.153, 2008.

M. D. Berardo, R. M. Elledge, C. De-moor, G. M. Clark, C. K. Osborne et al., Bcl-2 and apoptosis in lymph node positive breast carcinoma, Cancer, vol.82, pp.1296-302, 1998.

Y. H. Eom, H. S. Kim, A. Lee, B. J. Song, and C. Bj, BCL2 as a subtype-specific prognostic marker for breast Cancer, J Breast Cancer, vol.19, pp.252-60, 2016.

G. Gasparini, M. Barbareschi, C. Doglioni, P. D. Palma, F. A. Mauri et al., Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer, Clin Cancer Res, vol.1, pp.189-98, 1995.

K. T. Hwang, J. W. Woo, H. C. Shin, H. S. Kim, S. K. Ahn et al., Prognostic influence of BCL2 expression in breast cancer, Int J Cancer, vol.131, pp.1109-1128, 2012.

R. Silvestrini, S. Veneroni, M. G. Daidone, E. Benini, P. Boracchi et al., The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients, J Natl Cancer Inst, vol.86, pp.499-504, 1994.

S. J. Dawson, N. Makretsvov, F. M. Blows, K. E. Driver, E. Provenzano et al., BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received, Br J Cancer, vol.103, pp.668-75, 2010.

K. Hwang, W. Han, J. Kim, H. Moon, S. Oh et al., Prognostic influence of BCL2 on molecular subtypes of breast Cancer, J Breast Cancer, vol.20, pp.54-64, 2017.

M. Mccallum, C. Baker, K. Gillespie, B. Cohen, H. Stewart et al., A prognostic index for operable, node-negative breast cancer, Br J Cancer, vol.90, pp.1933-1974, 2004.

M. G. Lê, M. C. Mathieu, S. Douc-rasy, L. Bihan, M. L. et al., c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients, Int J Cancer, vol.84, pp.562-569, 1999.

S. Zinkel, A. Gross, and Y. E. , BCL2 family in DNA damage and cell cycle control, Cell Death Differ, vol.13, pp.1351-1360, 2006.

H. R. Ali, S. J. Dawson, F. M. Blows, E. Provenzano, S. Leung et al., A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer, J Pathol, vol.226, pp.97-107, 2012.

H. S. Kim, I. Park, H. J. Cho, G. Gwak, K. Yang et al., Analysis of the potent prognostic factors in luminal-type breast cancer, J Breast Cancer, vol.15, pp.401-407, 2012.

M. S. Larsen, K. Bjerre, A. Giobbie-hurder, A. V. Laenkholm, K. L. Henriksen et al., Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy, Acta Oncol, vol.51, pp.781-790, 2012.

M. K. Seong, J. Y. Lee, J. Byeon, Y. J. Sohn, H. Seol et al., Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer, Breast Cancer Res Treat, vol.150, pp.141-149, 2015.

T. M. Abdel-fatah, C. Perry, P. Dickinson, G. Ball, P. Moseley et al., Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings, Ann Oncol, vol.24, pp.2801-2808, 2013.

N. Honma, R. Horii, Y. Ito, S. Saji, M. Younes et al., Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy, BMC Cancer, vol.15, p.698, 2015.

A. A. Hayes and S. Mooney, Feline mammary tumors, Vet Clin North Am Small Anim Pract, vol.15, pp.513-533, 1985.

W. Misdorp and K. Weijer, Animal model of human disease: breast cancer, Am J Pathol, vol.98, pp.573-579, 1980.

F. Gimenez, S. Hecht, L. E. Craig, and A. M. Legendre, Early detection, aggressive therapy optimizing the management of feline mammary masses, J Feline Med Surg, vol.12, pp.214-238, 2010.

M. Castagnaro, C. Casalone, E. Bozzetta, D. Maria, R. Biolatti et al., Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas, J Comp Pathol, vol.119, pp.263-75, 1998.

M. Castagnaro, C. Casalone, G. Ru, G. C. Nervi, E. Bozzetta et al., Argyrophilic nucleolar organiser regions (AgNORs) count as indicator of post-surgical prognosis in feline mammary carcinomas, Res Vet Sci, vol.64, pp.97-100, 1998.

M. Castagnaro, D. Maria, R. Bozzetta, E. Ru, G. Casalone et al., Ki67 index as indicator of the post-surgical prognosis in feline mammary carcinomas, Res Vet Sci, vol.65, pp.223-229, 1998.

T. Ito, T. Kadosawa, M. Mochizuki, S. Matsunaga, R. Nishimura et al., Prognosis of malignant mammary tumor in 53 cats, J Vet Med Sci, vol.58, pp.723-729, 1996.

F. Millanta, M. Calandrella, S. Citi, D. Santa, D. Poli et al., Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential, Vet Pathol, vol.42, pp.30-34, 2005.

F. Seixas, C. Palmeira, M. A. Pires, M. J. Bento, and C. Lopes, Grade is an independent prognostic factor for feline mammary carcinomas: a clinicopathological and survival analysis, Vet J, vol.187, pp.65-71, 2011.

B. R. Madewell, R. Gandour-edwards, B. F. Edwards, J. E. Walls, and S. M. Griffey, Topographic distribution of bcl-2 protein in feline tissues in health and neoplasia, Vet Pathol, vol.36, pp.565-73, 1999.

T. Moriya, N. Kanomata, Y. Kozuka, M. Fukumoto, N. Iwachido et al., Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions, Breast Cancer, vol.16, pp.173-181, 2009.

M. M. Shamloula, S. H. El-shorbagy, and E. Saied, P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma, J Egypt Natl Canc Inst, vol.19, pp.202-212, 2007.

C. W. Elston and I. O. Ellis, Pathological prognostic factors in breast cancer: I. the value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, vol.19, pp.403-413, 1991.

S. W. Mills, K. M. Musil, J. L. Davies, S. Hendrick, C. Duncan et al., Prognostic value of histologic grading for feline mammary carcinoma: a retrospective survival analysis, Vet Pathol, vol.52, issue.2, pp.238-287, 2015.

J. Morris, Mammary tumors in the cat: size matters, so early intervention saves lives, J Feline Med Surg, vol.15, pp.391-400, 2013.

L. N. Owen and W. Health-organization, TNM classification of Tumours in domestic animals. Geneva: World Health Organization, 1980.

A. Gama, A. Alves, and F. Schmitt, Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification, Virchows Arch, vol.453, pp.123-155, 2008.

S. Guil-luna, R. Sánchez-céspedes, Y. Millán, D. Andrés, F. J. Rollón et al., Aglepristone decreases proliferation in progesterone receptorpositive canine mammary carcinomas, J Vet Intern Med, vol.25, pp.518-541, 2011.
DOI : 10.1111/j.1939-1676.2011.0723.x

F. Nguyen, L. Peña, C. Ibisch, D. Loussouarn, A. Gama et al., Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors, Breast Cancer Res Treat, vol.167, pp.635-683, 2018.
DOI : 10.1007/s10549-017-4548-2

URL : https://hal.archives-ouvertes.fr/inserm-01629625

M. Yi, L. Huo, K. B. Koenig, E. A. Mittendorf, F. Meric-bernstam et al., Which threshold for ER positivity? A retrospective study based on 9639 patients, Ann Oncol, vol.25, pp.1004-1015, 2014.
DOI : 10.1093/annonc/mdu053

URL : https://academic.oup.com/annonc/article-pdf/25/5/1004/16698055/mdu053.pdf

M. Soares, J. Correia, M. C. Peleteiro, and F. Ferreira, St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study, Tumour Biol, vol.37, pp.4053-64, 2016.
DOI : 10.1007/s13277-015-4251-z

M. Ono, H. Tsuda, M. Yunokawa, K. Yonemori, C. Shimizu et al., Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptorpositive, HER2-negative, node-negative invasive breast cancers, Breast Cancer, vol.22, pp.141-52, 2015.

M. Soares, R. Ribeiro, S. Carvalho, M. Peleteiro, J. Correia et al., Ki-67 as a prognostic factor in feline mammary carcinoma: what is the optimal cutoff value?, Vet Pathol, vol.53, issue.1, pp.37-43, 2016.

A. C. Wolff, M. E. Hammond, D. G. Hicks, M. Dowsett, L. M. Mcshane et al., Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, Arch Pathol Lab Med, vol.138, pp.241-56, 2014.

B. Brunetti, P. Asproni, G. Beha, L. V. Muscatello, F. Millanta et al., Molecular phenotype in mammary tumours of queens: correlation between primary tumour and lymph node metastasis, J Comp Pathol, vol.148, pp.206-219, 2013.

D. A. Wiese, T. Thaiwong, V. Yuzbasiyan-gurkan, and M. Kiupel, Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype, BMC Cancer, vol.13, p.403, 2013.
DOI : 10.1186/1471-2407-13-403

URL : https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-13-403

J. Chang, G. M. Clark, D. C. Allred, S. Mohsin, G. Chamness et al., Survival of patients with metastatic breast carcinoma, Cancer, vol.97, pp.545-53, 2003.
DOI : 10.1002/cncr.11083

URL : https://www.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.11083

P. Hellemans, P. A. Van-dam, J. Weyler, V. Oosterom, A. T. Buytaert et al., Prognostic value of bcl-2 expression in invasive breast cancer, Br J Cancer, vol.72, pp.354-60, 1995.

A. Bottini, A. Berruti, A. Bersiga, M. P. Brizzi, A. Brunelli et al., p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients, Clin Cancer Res, vol.6, pp.2751-2759, 2000.

H. H. Chen, W. C. Su, H. R. Guo, T. W. Chang, and W. Y. Lee, p53 and c-erbB-2 but not bcl-2 are predictive of metastasis-free survival in breast cancer patients receiving post-mastectomy adjuvant radiotherapy in Taiwan, Jpn J Clin Oncol, vol.32, pp.332-341, 2002.

E. Ermiah, A. Buhmeida, B. R. Khaled, F. Abdalla, N. Salem et al., Prognostic value of bcl-2 expression among women with breast cancer in Libya, Tumour Biol, vol.34, pp.1569-78, 2013.

M. Kyndi, F. B. Sørensen, H. Knudsen, J. Alsner, M. Overgaard et al., Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c, Acta Oncol, vol.47, pp.608-625, 2008.

E. Villar, M. Redondo, R. I. García, J. Avila, E. Matilla et al., Bcl-2 expression and apoptosis in primary and metastatic breast carcinomas, Tumour Biol, vol.22, pp.137-182, 2001.
DOI : 10.1159/000050608

G. J. Zhang, I. Kimijima, R. Abe, M. Kanno, N. Katagata et al., Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas, Clin Cancer Res, vol.3, pp.2329-2364, 1997.

G. J. Zhang, H. Tsuda, I. Adachi, T. Fukutomi, H. Yamamoto et al., Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins, Jpn J Clin Oncol, vol.27, pp.371-378, 1997.

A. El-hafez, A. Ael, -. Sm, and B. H. Elesawy, Different prognostic factors correlate with Bcl-2 expression among triple negative and non-triple negative breast cancers, Asian Pac J Cancer Prev, vol.14, pp.1037-1078, 2013.

J. Y. Lee, H. A. Kim, E. K. Kim, H. M. Yang, K. I. Kim et al., Different prognostic significance of Bcl-2 based on Cancer molecular subtype, J Breast Cancer, vol.14, issue.1, pp.10-16, 2011.

V. Bhargava, D. L. Kell, M. Van-de-rijn, and R. A. Warnke, Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity, Am J Pathol, vol.145, pp.535-575, 1994.

B. Biesaga, J. Niemiec, and M. Ziobro, BCL-2, topoisomerase II?, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy, J Cancer Res Clin Oncol, vol.140, pp.2009-2028, 2014.

H. Joensuu, L. Pylkkänen, and S. Toikkanen, Bcl-2 protein expression and longterm survival in breast cancer, Am J Pathol, vol.145, pp.1191-1199, 1994.

H. D. Lee, J. Y. Koo, and W. H. Jung, Correlations of Bcl-2 expression with clinicopathological features in breast cancer, Yonsei Med J, vol.38, pp.206-217, 1997.

B. Yu, X. Sun, H. Y. Shen, F. Gao, Y. M. Fan et al., Expression of the apoptosis-related genes BCL-2 and BAD in human breast carcinoma and their associated relationship with chemosensitivity, J Exp Clin Cancer Res, vol.29, p.107, 2010.

C. S. Escórcio-dourado, L. M. Martins, C. M. Simplício-revoredo, F. A. Sampaio, C. B. Tavares et al., Bcl-2 antigen expression in luminal a and triple-negative breast cancer, Med Oncol, vol.34, p.161, 2017.

L. K. Leung and T. T. Wang, Paradoxical regulation of Bcl-2 family proteins by 17beta-oestradiol in human breast cancer cells MCF-7, Br J Cancer, vol.81, pp.387-92, 1999.

J. M. Bhatavdekar, D. D. Patel, N. G. Shah, H. H. Vora, T. P. Suthar et al., Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis, Ann Surg Oncol, vol.7, pp.305-316, 2000.

G. M. Callagy, P. D. Pharoah, S. E. Pinder, F. D. Hsu, T. O. Nielsen et al., Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham prognostic index, Clin Cancer Res, vol.12, pp.2468-75, 2006.

F. Castiglione, I. Sarotto, V. Fontana, M. Destefanis, A. Venturino et al., p53 and clinical outcome in a series of 138 operable breast cancer patients, Anticancer Res, vol.19, pp.4555-63, 1999.

T. M. Abdel-fatah, D. G. Powe, G. Ball, M. A. Lopez-garcia, H. O. Habashy et al., Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer, J Pathol, vol.222, pp.388-99, 2010.

K. Tawfik, B. F. Kimler, M. K. Davis, F. Fan, and O. Tawfik, Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors, Hum Pathol, vol.43, pp.23-30, 2012.

B. D. Lehmann, J. A. Bauer, X. Chen, M. E. Sanders, A. B. Chakravarthy et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, vol.121, pp.2750-67, 2011.

F. C. Bidard, R. Conforti, T. Boulet, S. Michiels, S. Delaloge et al., Does triplenegative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers, Ann Oncol, vol.18, pp.1285-1291, 2007.

T. J. Mcdonnell and S. J. Korsmeyer, Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18), Nature, vol.349, pp.254-260, 1991.

J. M. Davis, P. M. Navolanic, C. R. Weinstein-oppenheimer, L. S. Steelman, W. Hu et al., Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance, Clin Cancer Res, vol.9, pp.1161-70, 2003.

O. Kutuk and A. Letai, Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737, Cancer Res, vol.68, pp.7985-94, 2008.

J. Y. Li, Y. Y. Li, J. W. Yang, Q. Shao, Z. M. Tian et al., ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL, J Exp Clin Cancer Res, vol.31, p.102, 2012.

J. A. Pietenpol, N. Papadopoulos, S. Markowitz, J. K. Willson, K. W. Kinzler et al., Paradoxical inhibition of solid tumor cell growth by bcl2, Cancer Res, vol.54, pp.3714-3721, 1994.

P. Juin, O. Geneste, F. Gautier, S. Depil, and M. Campone, Decoding and unlocking the BCL-2 dependency of cancer cells, Nat Rev Cancer, vol.13, pp.455-65, 2013.